Tag Archives: Flumazenil

Overview of New Anxiolytics

Although the benzodiazepines have been the treatment of choice for anxiety disorders for many years, unfavorable aspects to their side-effect profile have initiated efforts to develop new-generation antianxiety agents. Over the past decade, scientists have been searching for compounds that retain the robust anxiolytic efficacy of benzodiazepines, but lack a number of unwanted properties, including… Read More »

Substance-Related Disorders: Intervention

The cocaine and crack epidemic of the 1980s challenged traditional alcohol and drug treatment programs, because it resulted in a significant number of people being addicted not only to cocaine or crack but also to alcohol. It pointed out the failure of a system that separates alcoholism and chemical dependency, and it increased the importance… Read More »

Pharmacodynamic Effects of Anxiolytics

The evolution of the currently available anxiolytics is summarized in Figure Evolution of anxiolytic treatment.   Figure Evolution of anxiolytic treatment Benzodiazepines Specific benzodiazepine receptors were first identified in 1977 and have now been visualized in humans using autoradiographic, SPECT and PET techniques. They have been shown to be present solely in the grey matter… Read More »

Aetiology of Panic Disorder in Children and Adolescents

Neurochemical The biological basis for panic disorder was first hypothesized following the results of challenge studies with lactate which reliably precipitated panic attack symptoms in those with a panic disorder but not normal controls. Since then, a variety of other panic-inducing agents have been identified which produce similar results, carbon dioxide (C02), cholecystokinin (CCK), the… Read More »

Benzodiazepine Receptor Agonist Risks

Psychomotor Impairment Psychomotor impairment with benzodiazepine receptor agonists has been shown on various measures (i.e., as slowed reaction times, response errors, tracking errors, lapses of attention, and driving deviations) in laboratory performance testing and on actual roadway driving assessments. At their peak plasma concentrations benzodiazepine receptor agonist-associated impairments relate directly to the level of plasma… Read More »